Work for Rubius Therapeutics?

Claim Your Profile

Rubius Therapeutics Logo Image

Rubius Therapeutics

Rubius Therapeutics Banner Image

Most Recent Annual Report

Upgrade your company profile to unlock all of your annual report content on AnnualReports.co.uk

2018 Annual Report and Form 10K

Rubius Therapeutics

Rubius Therapeutics has reached its limit for free report views.

About Rubius Therapeutics

51-200 Employees
Based in Cambridge, Massachusetts

Rubius Therapeutics is a biopharmaceutical company pioneering a new era of cellular medicines. Their proprietary RED PLATFORM™ was designed to genetically engineer and culture Red Cell Therapeutics™ that are selective, potent and ready to-use cellular therapies for the potential treatment of several diseases across multiple therapeutic areas. Their initial focus is to advance RCT™ product candidates for the treatment of rare diseases, cancer and autoimmune diseases by leveraging three distinct therapeutic modalities — cellular shielding, potent cell-cell interaction and tolerance induction. They plan to file their first Investigational New Drug application (IND) for RTX-134 in phenylketonuria during the first quarter of 2019. They are planning to file additional INDs in rare diseases, cancer and autoimmune diseases in 2019, 2020 and beyond.

Ticker:
RUBY
Exchange:
NASDAQ (See More NASDAQ Companies)
Industry:
Biotechnology (See More Biotechnology Companies)
Sector:
Healthcare (See More Healthcare Companies)

Looking for Other Annual Reports?

Search by company name or ticker symbol